Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
J
J
Jahnel
H
H
Lackner
F
F
Reiterer
B
B
Urlesberger
C
C
Urban
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000175:diagnosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D057915:Drug Substitution; D005260:Female; D005500:Follow-Up Studies; D006390:Hemangioendothelioma / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D059885:Kasabach-Merritt Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D010976:Platelet Count; D011239:Prednisolone / Q000008:administration & dosage; D012186:Retroperitoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000188:drug therapy*; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects
D000893:Anti-Inflammatory Agents; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine; D011239:Prednisolone; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus